| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5482963 | STRIDES PHARMA | Pharmaceutical agents useful as leukotriene antagonists |
Jan, 2013
(11 years ago) | |
| US5612367 | STRIDES PHARMA | Method of enhancing bioavailability of pharmaceutical agents |
Mar, 2014
(10 years ago) | |
Accolate is owned by Strides Pharma.
Accolate contains Zafirlukast.
Accolate has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Accolate are:
- US5482963
- US5612367
Accolate was authorised for market use on 17 September, 1999.
Accolate is available in tablet;oral dosage forms.
Accolate can be used as enhancement of the bioavailability of the drug substance.
The generics of Accolate are possible to be released after 18 March, 2014.
Drugs and Companies using ZAFIRLUKAST ingredient
Market Authorisation Date: 17 September, 1999
Treatment: Enhancement of the bioavailability of the drug substance
Dosage: TABLET;ORAL
How can I launch a generic of ACCOLATE before it's drug patent expiration?
More Information on Dosage
ACCOLATE family patents
